Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics, Inc. develops allogeneic T-cell immunotherapies through an Epstein-Barr virus (EBV) T-cell platform for cancer and autoimmune disease programs. Company news centers on tabelecleucel, also referred to as tab-cel or EBVALLO, regulatory communications with the FDA, and collaboration activity with Pierre Fabre Pharmaceuticals for the EBV-positive post-transplant lymphoproliferative disease program.
Recurring updates also cover financial results, commercialization revenue, research and development spending, operational efficiency measures, milestone and royalty-related agreements, and equity-linked financing instruments such as warrants. Atara also reports on its inventory-based cell therapy approach, platform attributes that avoid T-cell receptor or HLA gene editing, and pipeline candidates including ATA3431 and ATA3219.
Atara Biotherapeutics (Nasdaq: ATRA) announced a 1-for-25 reverse stock split, effective June 20, 2024, to regain Nasdaq compliance and enhance share value. This split reduces the outstanding common stock from 122,606,575 shares to 4,904,263 shares. It does not impact authorized shares or par value. Adjustments will be made to equity awards and incentive plans. Stockholders will automatically see adjustments in their brokerage accounts, while those holding certificates will receive instructions from Computershare Trust Company. Fractional shares will be compensated in cash.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has announced the inducement grant of 9,700 restricted stock units (RSUs) to a newly hired employee. This grant, approved by the Compensation Committee of Atara's Board of Directors and issued under the 2018 Inducement Plan, is in line with Nasdaq Listing Rule 5635(c)(4). The RSUs are set to vest over four years; 25% will vest on the first quarterly vesting date after one year, with the remainder vesting in 12 equal quarterly installments over the next three years, contingent upon continuous employment.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, announced participation in the Goldman Sachs 45th Annual Global Healthcare Conference.
CEO Pascal Touchon and EVP Cokey Nguyen will join a fireside chat on June 12, 2024, at 6:20 a.m. PDT / 9:20 a.m. EDT.
The event will be webcast live on Atara’s website, with an archived replay available for 30 days.
Atara Biotherapeutics has announced promising preclinical data for ATA3219, an allogeneic CD19-targeted CAR T therapy aimed at treating B-cell driven autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). The data, to be presented at the ISCT 2024 Annual Meeting, show that ATA3219 effectively depletes CD19+ B-cells and induces lower levels of pro-inflammatory cytokines compared to autologous CD19 CAR T cells.
ATA3219 incorporates multiple clinically validated technologies, including a modified CD3ζ signaling domain and a less differentiated phenotype. A Phase 1 clinical trial for lupus nephritis (LN) and severe SLE without lymphodepletion is expected to begin in Q4 2024, with initial data anticipated in 2025.
Atara Biotherapeutics has submitted a Biologics License Application (BLA) to the U.S. FDA for tabelecleucel (tab-cel®), targeting Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) in patients aged two and older.
This marks the first allogeneic T-cell therapy BLA submission for the FDA. If approved, tab-cel would be the first FDA-approved therapy for EBV+ PTLD, potentially triggering milestone payments of up to $80 million from Pierre Fabre Laboratories.
Supported by data from over 430 patients, including a 48.8% Objective Response Rate from the ALLELE study, tab-cel has shown a favorable safety profile. The BLA submission is part of a broader global partnership with Pierre Fabre, which includes double-digit tiered royalties on net sales and reimbursement for development costs.
Atara Biotherapeutics announced its first-quarter 2024 financial results and operational progress, highlighting key advancements in its lead CAR T program, ATA3219, for oncology and autoimmune diseases. The company plans to submit a BLA for tab-cel in Q2 2024 and initiate studies for lupus nephritis and non-Hodgkin’s lymphoma. Atara's cash runway extends into 2027, enabling key pipeline readouts.
Atara Biotherapeutics, Inc. granted 4,150 restricted stock units to a newly hired employee under the Nasdaq Listing Rule 5635(c)(4). The stock units vest over four years, subject to continuous employment.
Summary not available.
Summary not available.
Summary not available.